News
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression (PPD) into the indication's standard of care.
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...
Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...
Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...
Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development. The companies are evaluating next steps, if any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback